NA-Selank Amidate
An N-acetylated, amidated form of Selank designed for enhanced stability and nasal bioavailability, studied for anxiolytic and nootropic effects via tuftsin-related immune modulation.
Also referenced as: N-Acetyl Selank Amidate, NASA
Also appears in: Immune
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Neuroprotection. Also surfaces under Immune for browsing and discovery.
N-Acetyl Selank Amidate, NASA
No FDA label signal · 449 trials · 15831 PubMed results
Current evidence for NA-Selank Amidate is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
NA-Selank Amidate has 2 name-matched clinical trials (highest phase: no phased trial) and 15831 PubMed-indexed publications and is not FDA-approved.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is NA-Selank Amidate?
NA-Selank Amidate is a modified version of Selank, a synthetic heptapeptide analog of tuftsin (the naturally occurring immunomodulatory peptide fragment of IgG). The modifications — N-acetylation at the N-terminus and amidation at the C-terminus — are designed to improve resistance to enzymatic degradation and extend the peptide’s biological half-life compared to unmodified Selank.
How it works
The core mechanism is shared with Selank:
- Tuftsin pathway — Selank is a synthetic extension of tuftsin (Thr-Lys-Pro-Arg), a tetrapeptide released from the Fc domain of IgG during phagocytosis. Tuftsin stimulates phagocytic activity of monocytes and neutrophils (Nishioka, Molecular and Cellular Biochemistry, 1979)
- GABA modulation — Selank has been shown to modulate GABA-A receptor sensitivity and influence BDNF expression in the hippocampus (Semenova et al., Doklady Biological Sciences, 2010)
- Anxiolytic effects — In preclinical models, Selank showed anxiolytic activity comparable to benzodiazepines without sedation or dependence (Seredenin et al., Bulletin of Experimental Biology and Medicine, 1998)
- Enhanced stability — the N-acetyl and amide modifications reduce aminopeptidase and carboxypeptidase degradation, extending the effective duration per administration
Research status
Selank (the parent peptide) has more clinical data than most research peptides, though primarily in Russian literature:
- Zozulya et al. (2008) reviewed the anxiolytic and nootropic properties of Selank in clinical and preclinical settings (Zhurnal Nevrologii i Psikhiatrii, 108(4):50–57)
- Seredenin et al. (1998) demonstrated anxiolytic effects of Selank in elevated plus-maze and conflict tests (Bulletin of Experimental Biology and Medicine, 126(4):1079–1082)
- Selank is approved in Russia as an intranasal anxiolytic (registration: PN002160)
The specific NA-Amidate modification has not been studied in published clinical trials — it is a vendor-driven formulation designed for improved stability.
Key considerations
- Selank (the parent compound) has Russian regulatory approval, which is unusual for research peptides
- The NA-Amidate form is not the version studied in clinical trials — it is a stability modification for the research market
- Typically administered intranasally from research vendors (spray formulations)
- Often stacked with NA-Semax Amidate, the analogous modified form of the nootropic peptide Semax